Image

A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer

Study on Circulating Tumor DNA (ctDNA) Minimal Residual Disease (MRD) Monitoring in Neoadjuvant Therapy for Pancreatic Cancer

Recruiting
18-75 years
All
Phase N/A
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study investigates borderline resectable pancreatic cancer. The purpose of this study is to explore the use of circulating tumor DNA (ctDNA) to monitor Minimal Residual Disease (MRD) in patients undergoing neoadjuvant therapy.

The study evaluates the relationship between MRD status and surgical outcomes, such as R0 resection rates, and survival outcomes including Disease-Free Survival (DFS) and Overall Survival (OS).

  • Who can participate: Adults aged 18 to 75 with confirmed pancreatic cancer that is high-risk resectable, borderline resectable, or locally advanced can participate. Participants must have a good performance status and be suitable for neoadjuvant therapy.
  • Study details: Participants will receive standard care decided by their doctors and have blood tests to check for MRD. A placebo is not used in this study.
  • Study timelines: The study will last 24 months.
Print
Study details
    Borderline Resectable Pancreatic Adenocarcinoma
    Resectable Pancreatic Adenocarcinoma

NCT07080021

Ruijin Hospital

31 July 2026

Contact a study center
Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.